Xenon Total Liab vs Long Term Debt Total Analysis

XENE Stock

USD 38.61 0.24 0.63%

Xenon Pharmaceuticals financial indicator trend analysis is more than just analyzing Xenon Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenon Pharmaceuticals is a good investment. Please check the relationship between Xenon Pharmaceuticals Total Liab and its Long Term Debt Total accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

Total Liab vs Long Term Debt Total

Total Liab vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenon Pharmaceuticals Total Liab account and Long Term Debt Total. At this time, the significance of the direction appears to have no relationship.

The correlation between Xenon Pharmaceuticals' Total Liab and Long Term Debt Total is 0.05. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Xenon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xenon Pharmaceuticals' Total Liab and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Xenon Pharmaceuticals are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Total Liab i.e., Xenon Pharmaceuticals' Total Liab and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.05

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Long Term Debt Total

Most indicators from Xenon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.At present, Xenon Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 3.1 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 2.65.

Xenon Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Common Stock Shares Outstanding		0.97	0.43	0.9	0.3	0.97	-0.46	0.96	0.01	-0.59	-0.98	0.98	0.66	0.87	0.84	0.76	0.96	0.52	0.98	-0.27	0.82	0.7	0.03	0.65	-0.45	0.96
Total Assets	0.97		0.37	0.88	0.3	1.0	-0.36	0.99	0.08	-0.71	-0.98	0.97	0.77	0.92	0.79	0.66	0.98	0.44	0.98	-0.2	0.75	0.76	0.08	0.65	-0.36	0.98
Short Long Term Debt Total	0.43	0.37		0.42	0.28	0.38	-0.68	0.27	-0.1	-0.05	-0.44	0.37	0.15	0.31	0.4	0.66	0.38	0.07	0.45	-0.4	0.4	0.26	-0.07	0.67	-0.61	0.38
Other Current Liab	0.9	0.88	0.42		0.39	0.88	-0.38	0.86	0.08	-0.38	-0.93	0.93	0.46	0.93	0.7	0.65	0.81	0.18	0.88	-0.22	0.59	0.66	0.12	0.49	-0.37	0.81
Total Current Liabilities	0.3	0.3	0.28	0.39		0.26	0.16	0.31	0.84	-0.06	-0.35	0.35	0.11	0.28	0.23	0.27	0.3	0.18	0.26	0.32	0.24	0.58	0.8	0.03	0.2	0.3
Total Stockholder Equity	0.97	1.0	0.38	0.88	0.26		-0.4	0.99	0.05	-0.71	-0.98	0.97	0.77	0.92	0.8	0.66	0.98	0.45	0.99	-0.24	0.76	0.74	0.03	0.67	-0.39	0.98
Other Liab	-0.46	-0.36	-0.68	-0.38	0.16	-0.4		-0.32	0.45	0.1	0.41	-0.39	-0.15	-0.27	-0.67	-0.48	-0.39	-0.28	-0.5	0.92	-0.53	0.0	0.67	-0.77	0.94	-0.39
Property Plant And Equipment Net	0.96	0.99	0.27	0.86	0.31	0.99	-0.32		0.14	-0.71	-0.96	0.97	0.76	0.89	0.82	0.62	0.98	0.51	0.97	-0.18	0.79	0.78	0.09	0.59	-0.31	0.98
Current Deferred Revenue	0.01	0.08	-0.1	0.08	0.84	0.05	0.45	0.14		-0.14	-0.05	0.08	0.13	0.05	0.04	-0.1	0.1	0.15	-0.01	0.47	0.01	0.5	0.8	-0.29	0.5	0.09
Net Debt	-0.59	-0.71	-0.05	-0.38	-0.06	-0.71	0.1	-0.71	-0.14		0.62	-0.54	-0.99	-0.58	-0.53	-0.37	-0.74	-0.55	-0.65	0.04	-0.5	-0.66	-0.03	-0.43	0.12	-0.74
Retained Earnings	-0.98	-0.98	-0.44	-0.93	-0.35	-0.98	0.41	-0.96	-0.05	0.62		-0.97	-0.7	-0.93	-0.79	-0.75	-0.95	-0.44	-0.98	0.21	-0.75	-0.74	-0.1	-0.64	0.4	-0.95
Accounts Payable	0.98	0.97	0.37	0.93	0.35	0.97	-0.39	0.97	0.08	-0.54	-0.97		0.61	0.91	0.79	0.65	0.95	0.39	0.97	-0.23	0.77	0.7	0.09	0.63	-0.39	0.95
Cash	0.66	0.77	0.15	0.46	0.11	0.77	-0.15	0.76	0.13	-0.99	-0.7	0.61		0.64	0.58	0.47	0.79	0.56	0.72	-0.05	0.53	0.7	0.05	0.47	-0.17	0.79
Non Current Assets Total	0.87	0.92	0.31	0.93	0.28	0.92	-0.27	0.89	0.05	-0.58	-0.93	0.91	0.64		0.61	0.52	0.84	0.13	0.89	-0.15	0.49	0.65	0.1	0.5	-0.26	0.84
Non Currrent Assets Other	0.84	0.79	0.4	0.7	0.23	0.8	-0.67	0.82	0.04	-0.53	-0.79	0.79	0.58	0.61		0.63	0.83	0.71	0.84	-0.58	0.86	0.62	-0.21	0.63	-0.57	0.83
Long Term Debt	0.76	0.66	0.66	0.65	0.27	0.66	-0.48	0.62	-0.1	-0.37	-0.75	0.65	0.47	0.52	0.63		0.68	0.52	0.73	-0.15	0.68	0.61	0.08	0.55	-0.49	0.69
Cash And Short Term Investments	0.96	0.98	0.38	0.81	0.3	0.98	-0.39	0.98	0.1	-0.74	-0.95	0.95	0.79	0.84	0.83	0.68		0.57	0.98	-0.22	0.83	0.78	0.06	0.68	-0.38	1.0
Net Receivables	0.52	0.44	0.07	0.18	0.18	0.45	-0.28	0.51	0.15	-0.55	-0.44	0.39	0.56	0.13	0.71	0.52	0.57		0.48	-0.2	0.74	0.48	-0.02	0.33	-0.26	0.57
Common Stock Total Equity	0.98	0.98	0.45	0.88	0.26	0.99	-0.5	0.97	-0.01	-0.65	-0.98	0.97	0.72	0.89	0.84	0.73	0.98	0.48		-0.32	0.81	0.71	-0.02	0.72	-0.5	0.98
Non Current Liabilities Total	-0.27	-0.2	-0.4	-0.22	0.32	-0.24	0.92	-0.18	0.47	0.04	0.21	-0.23	-0.05	-0.15	-0.58	-0.15	-0.22	-0.2	-0.32		-0.37	0.2	0.82	-0.6	0.85	-0.22
Other Current Assets	0.82	0.75	0.4	0.59	0.24	0.76	-0.53	0.79	0.01	-0.5	-0.75	0.77	0.53	0.49	0.86	0.68	0.83	0.74	0.81	-0.37		0.59	-0.09	0.73	-0.53	0.83
Other Stockholder Equity	0.7	0.76	0.26	0.66	0.58	0.74	0.0	0.78	0.5	-0.66	-0.74	0.7	0.7	0.65	0.62	0.61	0.78	0.48	0.71	0.2	0.59		0.49	0.26	0.05	0.78
Total Liab	0.03	0.08	-0.07	0.12	0.8	0.03	0.67	0.09	0.8	-0.03	-0.1	0.09	0.05	0.1	-0.21	0.08	0.06	-0.02	-0.02	0.82	-0.09	0.49		-0.36	0.65	0.06
Property Plant And Equipment Gross	0.65	0.65	0.67	0.49	0.03	0.67	-0.77	0.59	-0.29	-0.43	-0.64	0.63	0.47	0.5	0.63	0.55	0.68	0.33	0.72	-0.6	0.73	0.26	-0.36		-0.81	0.68
Preferred Stock Total Equity	-0.45	-0.36	-0.61	-0.37	0.2	-0.39	0.94	-0.31	0.5	0.12	0.4	-0.39	-0.17	-0.26	-0.57	-0.49	-0.38	-0.26	-0.5	0.85	-0.53	0.05	0.65	-0.81		-0.38
Total Current Assets	0.96	0.98	0.38	0.81	0.3	0.98	-0.39	0.98	0.09	-0.74	-0.95	0.95	0.79	0.84	0.83	0.69	1.0	0.57	0.98	-0.22	0.83	0.78	0.06	0.68	-0.38

Click cells to compare fundamentals

Xenon Pharmaceuticals Account Relationship Matchups

Xenon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	25.9M	34.5M	43.6M	60.5M	66.9M	70.2M
Total Assets	147.7M	189.2M	572.0M	754.1M	964.8M	1.0B
Short Long Term Debt Total	16.5M	3.3M	8.3M	10.4M	10.9M	10.0M
Other Current Liab	6.3M	7.8M	605K	13.7M	17.4M	18.2M
Total Current Liabilities	43.4M	14.8M	14.3M	22.7M	27.3M	17.3M
Total Stockholder Equity	92.0M	171.4M	550.0M	721.5M	927.9M	974.3M
Property Plant And Equipment Net	2.6M	6.9M	12.5M	16.9M	18.8M	19.8M
Net Debt	(8.3M)	(41.7M)	(167.4M)	(46.8M)	(137.7M)	(130.9M)
Retained Earnings	(249.7M)	(278.5M)	(357.4M)	(482.7M)	(665.1M)	(631.9M)
Accounts Payable	2.5M	3.0M	3.8M	8.5M	8.6M	9.0M
Cash	24.8M	45.0M	175.7M	57.2M	148.6M	156.1M
Non Current Assets Total	2.8M	7.4M	13.0M	153.8M	319.8M	335.8M
Non Currrent Assets Other	2.6M	7.4M	8.1M	7.8M	7.4M	7.8M
Cash And Short Term Investments	141.4M	177.0M	551.8M	592.1M	638.1M	670.0M
Net Receivables	813K	1.8M	2.8M	986K	874K	872.3K
Common Stock Total Equity	294.2M	397.7M	783.2M	1.1B	1.2B	1.3B
Liabilities And Stockholders Equity	147.7M	189.2M	572.0M	754.1M	964.8M	1.0B
Non Current Liabilities Total	12.3M	3.1M	7.7M	9.9M	9.6M	7.2M
Other Current Assets	2.7M	4.8M	7.2M	8.2M	6.0M	3.3M
Other Stockholder Equity	40.6M	45.4M	117.5M	142.1M	156.8M	164.6M
Total Liab	55.7M	17.8M	22.0M	32.6M	36.9M	27.2M
Total Current Assets	144.9M	181.8M	559.0M	600.3M	645.0M	677.2M
Common Stock	294.2M	397.7M	783.2M	1.1B	1.4B	1.5B
Property Plant Equipment	1.7M	3.6M	4.5M	6.5M	7.5M	7.8M
Net Tangible Assets	84.2M	163.6M	542.3M	721.5M	829.7M	871.2M
Other Assets	238K	523K	465K	143.7M	306.2M	321.5M
Short Term Investments	116.6M	132.0M	376.1M	534.8M	489.4M	513.9M
Retained Earnings Total Equity	(249.7M)	(278.5M)	(357.4M)	(482.7M)	(434.5M)	(412.7M)
Capital Surpluse	40.6M	45.4M	117.5M	142.1M	163.4M	171.6M
Net Invested Capital	99.8M	163.6M	542.3M	721.5M	927.9M	974.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:

How To Invest In Xenon

Details

Is Xenon Stock a good investment?

Details

What is Xenon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Xenon Stock analysis

When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Is Xenon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.72)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.17)

Return On Equity

(0.24)

The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xenon Total Liab vs Long Term Debt Total Analysis

Total Liab vs Long Term Debt Total

Total Liab vs Long Term Debt Total Correlation Analysis

Correlation Coefficient

Total Liab

Long Term Debt Total

Xenon Pharmaceuticals fundamental ratios Correlations

Xenon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xenon Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Xenon Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Common Stock Total Equity	+ 0.99	Total Stockholder Equity
Accounts Payable	+ 0.98	Common Stock Shares Outstanding

Cash	- 0.99	Net Debt
Common Stock Total Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.98	Total Assets
Retained Earnings	- 0.98	Common Stock Shares Outstanding
Accounts Payable	- 0.97	Retained Earnings